Thromb Haemost 1986; 55(03): 325-329
DOI: 10.1055/s-0038-1661556
Original Article
Schattauer GmbH Stuttgart

Blood Platelet Plasminogen Activator Inhibitor: Two Different Pools of Endothelial Cell Type Plasminogen Activator Inhibitor in Human Blood

E D Sprengers
1   The TNO Gaubius Institute for Cardiovascular Research, Leiden, The Netherlands
,
J W N Akkerman
2   The Department of Haematology, University Hospital Utrecht, Utrecht, The Netherlands
,
B G Jansen
1   The TNO Gaubius Institute for Cardiovascular Research, Leiden, The Netherlands
› Author Affiliations
Further Information

Publication History

Received 06 December 1985

Accepted after revision 07 March 1986

Publication Date:
18 July 2018 (online)

Summary

An assay for plasminogen activator inhibitor in human platelets is described. With this assay we find an average value of 6.8 × 10−8 IU/platelet (S.D. = 3.0 × 10−8; n = 20) in a healthy population. We characterized the PA-inhibitor from platelets and identified it as endothelial cell type plasminogen activator inhibitor, by its immunologic and functional properties. Besides the plasma pool of plasminogen activator inhibitor with a very high turnover rate, platelets constitute a second pool of plasminogen activator inhibitor in the circulation of the same order of magnitude. The two different pools of plasminogen activator inhibitor might have a different physiologic function.

 
  • References

  • 1 Emeis JJ, Brommer EJ P, Kluft C, Brakman P. Progress in fibrinolysis. In Recent Adv Blood Coagulation Poller L. (Ed) 11-33 Churchill Livingstone; Edinburgh: 1985
  • 2 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1983; 43: 77-89
  • 3 Danø K, Andreasen PA, Grøndahl-Handen I, Kristensen P, Nielsen LS, Skriver L. Plasminogen activators, tissue degradation and cancer. Adv in Cancer Res 1985; 44: 139-266
  • 4 Verheijen JH, Chang GT G, Kluft C. Evidence for the occurrence of a fast-acting inhibitor of plasminogen activator in human plasma. Thromb Haemostas 1984; 51: 392-395
  • 5 Kruithof EK O, Tran-Thang C, Ransijn A, Bachmann F. Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood 1984; 64: 907-913
  • 600 Wiman B, Chmielewska I, Rånby M. Inactivation of tissue plasminogen activator in plasma. J Biol Chem 1984; 259: 3644-3647
  • 7 Thorsen S, Philips M. Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma. Biochim Biophys Acta 1984; 802: 111-118
  • 8 Juhan-Vague I, Moerman B, De Cock F, Ailland MF, Collen D. Plasma levels of a specific inhibitor of tissue-type plasminogen activator (and urokinase) in normal and pathological conditions. Thromb Res 1984; 33: 523-530
  • 9 Korninger C, Wagner O, Binder BR. Tissue plasminogen activator inhibitor in human plasma: Development of a functional assay system and demonstration of a correlating Mr = 50,000 antiactivator. J Lab Clin Med 1985; 105: 718-724
  • 10 Sprengers ED. A sensitive assay, specific for endothelial cell type plasminogen activator inhibitor in blood plasma. Thromb Haemostas 1986; 55: 74-77
  • 11 Golder JP, Stephens RW. Minactivin: a human monocyte product which specifically inactivates urokinase-type plasminogen activators. Eur J Biochem 1983; 136: 517-522
  • 12 Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterisation of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465-1472
  • 13 Booth NA, Anderson JA, Bennett B. Platelets release protein which inhibits plasminogen activators. J Clin Pathol 1985; 38: 825-830
  • 14 Holmberg L, Lecander I, Persson B, Åstedt B. An inhibitor from placenta specifically binds urokinase and inhibits plasminogen activator released from ovarian carcinoma in tissue culture. Biochim Biophys Acta 1978; 544: 128-137
  • 15 Wijngaards G. Interfering factors in the assay of plasminogen activators by the fibrin plate method. Thromb Haemostas 1979; 41: 590-600
  • 16 Lecander I, Roblin R, Åstedt B. Differential inhibition of two molecular forms of melanoma cell plasminogen activator by a placental inhibitor. Brit J Haematol 1984; 57: 407-412
  • 17 Dosne AM, Dupuy E, Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978; 12: 377-387
  • 18 Esnard F, Dupuy E, Dosne AM, Bodevin E. Partial characterization of a fibrinolytic inhibitor produced by cultured endothelial cells derived from human umbilical vein. Thromb Haemostas 1982; 47: 128-131
  • 19 Emeis JJ, Van Hinsbergh VW M, Verheijen JH, Wijngaards G. Inhibition of tissue-type plasminogen activator by conditioned medium from cultured human and porcine vascular endothelial cells. Biochem Biophys Res Comm 1983; 110: 392-398
  • 20 Levin EG. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-6808
  • 21 Loskutoff DJ, Van Mourik JA, Erickson LA, Lawrence D. Detection of an unusually stable fibrinolytic inhibitor produced by bovine endothelial cells. Proc Natl Acad Sci USA 1983; 80: 2956-2960
  • 22 Sprengers ED, Verheijen JH, Van Hinsbergh VW M, Emeis JJ. Evidence for the presence of two different fibrinolytic inhibitors in human endothelial cell conditioned medium. Biochim Biophys Acta 1984; 801: 163-170
  • 23 Philips M, Juul A, Thorsen S. Human endothelial cells produce a plasminogen activator inhibitor and a tissue-type plasminogen activator-inhibitor complex. Biochim Biophys Acta 1984; 802: 99-110
  • 24 Van Mourik JA, Lawrence DA, Loskutoff DJ. Purification of an inhibitor of plasminogen activator (anti-activator) synthesized by endothelial cells. J Biol Chem 1984; 259: 14914-14921
  • 25 Sprengers ED, Princen HM G, Kooistra T, Van Hinsbergh VW M. Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2. J Lab Clin Med 1985; 105: 751-758
  • 26 Thorsen S, Brakman P, Astrup T. Influence of platelets on fibrinolysis. A critical review. In Hematologic Reviews. Vol 3 Ambrus JL. (ed) Marcel Dekker; New York: 1972: 123-179
  • 27 Ludlam CA, Cash JD. Studies on the liberation of β-thromboglobulin from human platelets in vitro. Brit J Haematol 1976; 33: 239-247
  • 28 Walsh PN. Albumin density gradient separation and washing of platelets and the study of platelet coagulant activities. Brit J Haematol 1972; 22: 205-217
  • 29 Kluft C, Van Wezel AL, Van der Velden CA M, Emeis JJ, Verheijen JH, Wijngaards G. Large-scale production of extrinsic (tissue-type) plasminogen activator from human melanoma cells. In Advances in Biotechnological Processes Mizrahi A, Van Wezel AL. (Eds) Alan R Liss; New York: 1983. 2 97-110
  • 30 Gaffney PJ, Curtis AD. A collaborative study of a proposed international standard for tissue-type plasminogen activator (t-PA). Thromb Haemostas 1985; 53: 134-136
  • 31 Verheijen JH, Sprengers ED, Emeis JJ, Van Hinsbergh VW M, Chang GT G, Kluft C. Tissue-plasminogen activator inhibition by human endothelial cell conditioned medium and plasma. In Progress in Fibrinolysis VII Davidson JF, Donati MB, Coccheri S. (Eds) Churchill Livingstone; Edinburgh: 1985: 141-145
  • 32 Laemmli UK. Cleavage of structural proteins during the assembly of the head of backriophage T4. Nature 1970; 277: 680-685
  • 33 Sprengers ED, Van Hinsbergh VW M, Jansen BG. Relationship between the fast-acting and the latent plasminogen activator inhibitor, secreted by human endothelial cells. Thromb Haemostas 1985; 54: 299 (Abstr)
  • 34 Barlow RB. Biodata handling with microcomputers. 1983: 12-15 Elsevier Science Publishers;
  • 35 Kluft C, Jie AF H, Sprengers ED, Verheijen JH. Identification of a reversible inhibitor of plasminogen activators in blood plasma. FEBS Letters 1985; 190: 315-318
  • 36 Van Hinsbergh VW M, Bertina RM, Van Wijngaarden A, Van Tilburg NH, Emeis JJ, Haverkate F. Activated protein C decreases plasminogen activator-inhibitor activity in endothelial cell-conditioned medium. Blood 1985; 65: 444-451
  • 37 Colucci M, Paramo JM, Collen D. Generation in plasma of a fast-acting inhibitor of plasminogen activator in response to endotoxin stimulation. J Clin Invest 1984; 75: 818-824